Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.

Literature DB >> 19116373

Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.

Abstract

Glucagon is secreted from the alpha-cells of the pancreatic islets and regulates glucose homeostasis through modulation of hepatic glucose production. As elevated glucagon levels contribute to the pathophysiology of hyperglycemia in subjects with type 2 diabetes, reduction of glucagon receptor gene (Gcgr) activity represents a potential target for the treatment of T2DM. Herein, we review current concepts of glucagon action in hepatic and extrahepatic tissues and evaluate the therapeutic potential, mechanisms of action, and safety of reducing Gcgr signaling for the treatment of T2DM.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2008 PMID： 19116373 DOI： 10.1152/ajpendo.90887.2008

Source DB: PubMed Journal: Am J Physiol Endocrinol Metab ISSN： 0193-1849 Impact factor: 4.310

Keyword Cloud
Cited

50 in total

Review 1. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

Authors: Philip E Cryer
Journal: Endocrinology Date: 2011-12-13 Impact factor: 4.736

2. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.

Authors: Y Takeda; Y Fujita; J Honjo; T Yanagimachi; H Sakagami; Y Takiyama; Y Makino; A Abiko; T J Kieffer; M Haneda
Journal: Diabetologia Date: 2011-11-10 Impact factor: 10.122

Review 3. Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.

Authors: Xiao C Li; Jia L Zhuo
Journal: Curr Hypertens Rep Date: 2013-10 Impact factor: 5.369

4. Islets of Langerhans from prohormone convertase-2 knockout mice show α-cell hyperplasia and tumorigenesis with elevated α-cell neogenesis.

Authors: Huw B Jones; Jaimini Reens; Simon R Brocklehurst; Catherine J Betts; Sue Bickerton; Alison L Bigley; Richard P Jenkins; Nicky M Whalley; Derrick Morgan; David M Smith
Journal: Int J Exp Pathol Date: 2014-02 Impact factor: 1.925

Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.

Review 1. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

2. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.

Review 3. Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.

4. Islets of Langerhans from prohormone convertase-2 knockout mice show α-cell hyperplasia and tumorigenesis with elevated α-cell neogenesis.

5. Per-arnt-sim (PAS) domain kinase (PASK) as a regulator of glucagon secretion.

6. Glucagon's effect on liver protein metabolism in vivo.

Review 7. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?

Review 8. Islet α cells and glucagon--critical regulators of energy homeostasis.

Review 9. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.

10. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.